tetano
Editor, Senior Moderator
Vaccines (Basel)
. 2021 Nov 15;9(11):1324.
doi: 10.3390/vaccines9111324.
Transdermal Vaccination with the Matrix-2 Protein Virus-like Particle (M2e VLP) Induces Immunity in Mice against Influenza A Virus
Kimberly Braz Gomes[SUP] 1 [/SUP], Sucheta D'Sa[SUP] 1 [/SUP], Grace Lovia Allotey-Babington[SUP] 1 [/SUP], Sang-Moo Kang[SUP] 2 [/SUP], Martin J D'Souza[SUP] 1 [/SUP]
Affiliations
Abstract
In this study, our goal was to utilize the extracellular domain matrix-2 protein virus-like particle (M2e VLP) that has been found to be highly conserved amongst all strains of influenza and could serve as a potential vaccine candidate against influenza. Previous studies have demonstrated that the VLP of the M2e showed increased activation of innate and adaptive immune responses. Therefore, to further explore its level of efficacy and protection, this vaccine was administered transdermally and tested in a pre-clinical mouse model. The M2e VLP was encapsulated into a polymeric matrix with the addition of Alhydrogel[SUP]®[/SUP] and Monophosphoryl Lipid-A (MPL-A[SUP]®[/SUP]), together referred to as AS04. The M2e VLP formulations induced IgG titers, with increased levels of IgG1 in the M2e VLP MP groups and further elevated levels of IgG2a were found specifically in the M2e VLP MP Adjuvant group. This trend in humoral immunity was also observed from a cell-mediated standpoint, where M2e VLP MP groups showed increased expression in CD4[SUP]+[/SUP] T cells in the spleen and the lymph node and high levels of CD8[SUP]+[/SUP] T cells in the lymph node. Taken together, the results illustrate the immunogenic potential of the matrix-2 protein virus-like particle (M2e VLP) vaccine.
Keywords: influenza A virus; transdermal; virus-like particles (VLPs).
. 2021 Nov 15;9(11):1324.
doi: 10.3390/vaccines9111324.
Transdermal Vaccination with the Matrix-2 Protein Virus-like Particle (M2e VLP) Induces Immunity in Mice against Influenza A Virus
Kimberly Braz Gomes[SUP] 1 [/SUP], Sucheta D'Sa[SUP] 1 [/SUP], Grace Lovia Allotey-Babington[SUP] 1 [/SUP], Sang-Moo Kang[SUP] 2 [/SUP], Martin J D'Souza[SUP] 1 [/SUP]
Affiliations
- PMID: 34835255
- PMCID: PMC8619166
- DOI: 10.3390/vaccines9111324
Abstract
In this study, our goal was to utilize the extracellular domain matrix-2 protein virus-like particle (M2e VLP) that has been found to be highly conserved amongst all strains of influenza and could serve as a potential vaccine candidate against influenza. Previous studies have demonstrated that the VLP of the M2e showed increased activation of innate and adaptive immune responses. Therefore, to further explore its level of efficacy and protection, this vaccine was administered transdermally and tested in a pre-clinical mouse model. The M2e VLP was encapsulated into a polymeric matrix with the addition of Alhydrogel[SUP]®[/SUP] and Monophosphoryl Lipid-A (MPL-A[SUP]®[/SUP]), together referred to as AS04. The M2e VLP formulations induced IgG titers, with increased levels of IgG1 in the M2e VLP MP groups and further elevated levels of IgG2a were found specifically in the M2e VLP MP Adjuvant group. This trend in humoral immunity was also observed from a cell-mediated standpoint, where M2e VLP MP groups showed increased expression in CD4[SUP]+[/SUP] T cells in the spleen and the lymph node and high levels of CD8[SUP]+[/SUP] T cells in the lymph node. Taken together, the results illustrate the immunogenic potential of the matrix-2 protein virus-like particle (M2e VLP) vaccine.
Keywords: influenza A virus; transdermal; virus-like particles (VLPs).